Search

everythinglearnresearchcommunity

for

Search:↓

The formula YH0618 can reduce the harmful side effects of the chemotherapy drug Doxorubicin and protect healthy cells.

JAK inhibitors show promise in treating difficult skin diseases.

A man treated with gefitinib for lung cancer grew new hair on his bald scalp.

Tofacitinib helped a person with total body hair loss grow hair again without bad side effects.

A new compound shows promise as a topical treatment for hair loss.

Tofacitinib improved arthritis and partially improved hair loss in a lupus patient without side effects.

UTMD with diclofenac and Doxil® improves cancer treatment by boosting immune response and reducing tumor-supporting cells.

Tofacitinib effectively treated severe hair loss in a patient who didn't respond to other treatments.

Mutant MK6a transgenes in mice cause blistering, hair loss, and potential human alopecia.

QLT0267 stops hair follicle cell growth and movement.

Vitamin D receptor helps prevent skin tumors.

Ruxolitinib can help regrow hair in severe alopecia areata.

Baricitinib and its combination with lonafarnib improve fat cell formation in certain genetic disorders.

New treatments for a type of skin cancer show promise but have side effects and may work better with other therapies.

Combining hair transplantation with PRP is more effective for treating hair loss than hair transplantation alone.

Deleting the Trf1 protein in mice is safe and may help prevent cancer without major side effects.

Ruxolitinib reduced inflammation and improved symptoms in APECED patients but may cause anemia and weight gain.

Skin side effects from CDK4/6 inhibitors in breast cancer patients are generally mild and treatable, allowing most patients to continue treatment.

Combining baricitinib with UV-B therapy effectively treats non-segmental vitiligo and is well-tolerated.

PF-998425 is a new, effective, and non-phototoxic treatment for skin conditions related to androgens.

Ruxolitinib and tofacitinib are effective and safe for treating severe alopecia areata.

Upadacitinib effectively treats pyoderma gangrenosum.

Sorafenib causes skin reactions by increasing the number and activity of skin mast cells.

Using 2% tofacitinib cream with narrowband ultraviolet B improved facial vitiligo by 70% in patients who didn't respond to previous treatments, with no side effects reported.

KIT's role in skin cells is not entirely independent, as other cells can influence its function.

Tofacitinib helped psoriasis but not alopecia universalis, needing more research.

Tofacitinib is a promising treatment for children with rheumatic diseases.

B-Raf and C-Raf are essential for maintaining melanocyte stem cells to prevent hair graying.

Upadacitinib may effectively treat both alopecia universalis and Crohn's disease.

Upadacitinib significantly improved both rheumatoid arthritis and alopecia areata in a patient.